ERBB2 and breast carcinoma: Although breast cancer (BC) is not traditionally considered immunogenic 68, increasing evidence suggests that its specific molecular subtypes, namely triple-negative and HER2-positive subtypes, often correlate with substantial infiltration of immune cells with a particular prognostic and even predictive value 73.